VectorY

Weer een stap vooruit in de strijd tegen ALS.

VectorY Publishes Groundbreaking Research on ALS Treatment VectorY is proud to announce the publication (DOI: https://lnkd.in/ehwCB5dw) of a significant research paper that sheds light on the mechanisms driving motor neuron death in ALS (Amyotrophic Lateral Sclerosis) patients. The study shows that oxidized phosphatidylcholines (PC-OxPL) carried by apoE particles in the cerebrospinal fluid (CSF) of ALS patients induce the aggregation of TDP-43, a protein linked to motor neuron death. This research highlights the potential of VectorY's innovative vectorized antibody treatment, VTx-001, which specifically recognizes and neutralizes PC-OxPL neoepitopes. VTx-001 has been thus shown to prevent TDP-43 aggregation and protect motor neurons from death. The publication of this paper marks a milestone in VectorY's ongoing commitment to advancing medical research and developing innovative therapies for neurodegenerative diseases. #VectorY #GeneTherapy #biotechnology #biotech

Exciting opening at VectorY for a (senior) Bio Assay scientist! PhD in molecular biology, cell biology, and/or molecular virology and minimum 5 years of industry experience is a must. Check out this vacancy: https://lnkd.in/eu9hG9fP #VectorY #ALS #biotech #genetherapy #research #PhD #industryexperience #bioassay #career #opportunity #celbiology #molecularbiology #molecularvirology #Amsterdam #sciencepark #scientist

And 2 more promotions at VectorY! Congrats to Marina Sogorb González, PhD who has been promoted to senior scientist. Also many congrats to @Martino Böhne who has been promoted to labmanager. Well deserved!

Many congratulatinss to these VectorYans who were promoted. Well deserved! Danny Huang technician Ties Baljet technician Melanie Ofman : senior technician Jelmer Willems : senior scientist Good luck in your new roles.

Welcome to Jim Scibetta, our newly appointed CEO! Jim brings more than 20 years of executive leadership experience, building earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies. Former CEO and founder Sander van Deventer, will become President of R&D, and will continue to drive the development of VectorY’s pipeline including the lead program, VTx-002. For the full release, please visit: https://lnkd.in/ecxAbxfk #VectorY #GeneTherapy #Neurodegeneration #biotechnology #biotech #BiotechTV

We are hiring! For our research team, we are seeking for a enthusiastic technician with iPSC experience. Interested to join VectorY? Check out this great opportunity! https://lnkd.in/eKmX8HEm #vectory #technician #genetherapy #vacancy #opportunity #biotech #ALS #iPSC #sciencepark #Amsterdam #careeropportunity

London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year. CEO Sander van Deventer describes the science behind delivering antibodies this way, and learnings he has taken away from the gene therapy field. https://lnkd.in/gJjR5p3P #VectorY #GeneTherapy #Neurodegeneration #biotechnology #biotech #BiotechTV

Giulia De Sabbata (head of Discovery) and Jelmer Willems (scientist Vector Development) from VectorY are set to attend the European Society of Gene & Cell Therapy conference in Rome from October 22-25. On October 22, Jelmer Willems will present a poster showcasing the latest advancements in AAV vector design. Don't miss out on the presentation at P0103, focused on optimizing the baculovirus generation process and introducing a novel ITR-transgene design for top-notch AAV production using the insect cell production platform. #VectorY #GeneTherapy #neurodegeneration #AAV www.vectorytx.com www.esgctcongress.com

We are very happy to welcome a new enthusiastic and great scientist to our VectorY Assay Development team! Good luck Wendy van Zuijlen, PhD. #VectorY #newscientist #wendyvanzuijlen #genetherapy #biotech #assaydevelopment #amsterdam #sciencepark #vectoryans #newemployee #newcareer #ALS